Shots:
Variant Bio has expanded its multi-year research collaboration & license agreement with BI to discover and validate novel cardiovascular disease targets using its Inference platform, building on their existing kidney disease collaboration
As per the terms of the expanded agreement, Variant Bio will receive an additional upfront payment & over $250M in potential license…
